精神病學合作夥伴關係和許可協議（2019-2024）

Psychiatry Collaboration and Licensing Deals 2019-2024

出版日期: 2024年10月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告審查了 2016 年至 2024 年期間與精神病學相關的 541 份合作夥伴關係和許可協議，並審查了交易總數、財務交易狀況以及交易活躍度最高的 25 家公司的趨勢。、合約文件等

主要優點

該報告為讀者提供了以下主要好處：

了解 2016 年以來的合約趨勢
查看業務夥伴交易
基準分析：確定交易的市場價值
財務狀況
交易清單：按公司名稱 (A-Z)、治療領域和技術類型
主要交易（金額基礎）
最活躍的談判者
每筆交易的資產識別和交易條件
取得合約文件：深入了解交易結構
盡職調查：評估擬議交易條款對合作夥伴公司的適用性
節省數百小時的研究時間

合約分析允許盡職調查：

授予/選擇了哪些權利？
合約授予了哪些權利？
授予哪些類型的專有權？
合約的付款結構為
如何審核銷售和付款？
合約期限為
合約的主要條款是如何定義的？
如何對待和擁有知識產權？
誰負責商業化？
誰負責開發、供應和製造？
如何管理保密和發布？
如何解決爭議？
什麼情況下可以取消合約？
如果所有者發生變化會怎樣？
已就哪些從屬許可或分包條款達成協議？
公司需要哪些樣板條款？
哪些樣板條款看起來有所不同，取決於合作夥伴和交易類型？
每家公司對契約法主張哪一個管轄權？

精神科領域的交易：依治療目標分類
交易目錄
交易目錄：依公司劃分（2016-2024 年）
貿易名錄：依技術類型分類（2016-2024 年）
交易類型的定義
關於生物製藥研究股份有限公司
目前的合作關係
當前合約
Current Partnering 最近的報告標題

簡介目錄

Product Code: CP2204

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 541 psychiatry deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse psychiatry collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

Trends in psychiatry dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of psychiatry deal records covering pharmaceutical and biotechnology
The leading psychiatry deals by value
Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?